'Not in today's market': As Amgen, Bristol Myers back antibody startup BigHat, bear market keeps IPO window shut tight

Max Gelman

Senior Editor

A private antibody startup is pulling in some new cash to continue advancing its discovery-stage programs, recruiting some big backers in the process. But in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

'Not in today's market': As Amgen, Bristol Myers back antibody startup BigHat, bear market keeps IPO window shut tight

Max Gelman

Senior Editor

Sign up to read this article for free.

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

'Not in to­day's mar­ket': As Am­gen, Bris­tol My­ers back an­ti­body start­up BigHat, bear mar­ket keeps IPO win­dow shut tight

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

'Not in today's market': As Amgen, Bristol Myers back antibody startup BigHat, bear market keeps IPO window shut tight

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope